Skip to main content
. 2016 Dec;6(4):498–507. doi: 10.1086/688489

Figure 5.

Figure 5

Median (interquartile range) macrophage migration inhibitory factor (MIF) levels in controls, patients with portopulmonary hypertension (POPH), and patients with non-POPH group 1 pulmonary arterial hypertension (PAH). Central vein (CV) MIF levels are higher in an external cohort of patients with POPH (38.85 ng/mL [32.9–66.0]; n = 27) compared with liver disease controls (31.2 ng/mL [26.9–42.2]; n = 31) but are not significantly different from patients with non-POPH group 1 PAH (44.1 ng/mL [30.3–53.6]; n = 21).